Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Ranolazine

Mirembe Reed, Shwetha Gopal  1 , Mark V. Pellegrini, Diala Nicolas  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Ranolazine

Mirembe Reed et al.
Free Books & Documents

Excerpt

This activity focuses on ranolazine, an FDA-approved medication for the management of chronic angina associated with ischemic heart disease. Aimed at optimizing the treatment of stable angina, the primary objective is to alleviate ischemic symptoms, minimize their occurrence, and reduce the risk of myocardial infarction and mortality. In conjunction with standard therapies such as aspirin, P2Y12 inhibitors, ACEIs, angiotensin receptor blockers, statins, beta-blockers, calcium channel blockers, and nitrates, ranolazine serves as an adjunct therapy, enriching the overall strategy for angina management.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Mirembe Reed declares no relevant financial relationships with ineligible companies.

Disclosure: Shwetha Gopal declares no relevant financial relationships with ineligible companies.

Disclosure: Mark Pellegrini declares no relevant financial relationships with ineligible companies.

Disclosure: Diala Nicolas declares no relevant financial relationships with ineligible companies.

References

    1. Reddy BM, Weintraub HS, Schwartzbard AZ. Ranolazine: a new approach to treating an old problem. Tex Heart Inst J. 2010;37(6):641-7. - PMC - PubMed
    1. Al Batran R, Gopal K, Aburasayn H, Eshreif A, Almutairi M, Greenwell AA, Campbell SA, Saleme B, Court EA, Eaton F, Light PE, Sutendra G, Ussher JR. The antianginal ranolazine mitigates obesity-induced nonalcoholic fatty liver disease and increases hepatic pyruvate dehydrogenase activity. JCI Insight. 2019 Jan 10;4(1) - PMC - PubMed
    1. Teoh IH, Banerjee M. Effect of ranolazine on glycaemia in adults with and without diabetes: a meta-analysis of randomised controlled trials. Open Heart. 2018;5(2):e000706. - PMC - PubMed
    1. Pavasini R, Camici PG, Crea F, Danchin N, Fox K, Manolis AJ, Marzilli M, Rosano GMC, Lopez-Sendon JL, Pinto F, Balla C, Ferrari R. Anti-anginal drugs: Systematic review and clinical implications. Int J Cardiol. 2019 May 15;283:55-63. - PubMed
    1. Banon D, Filion KB, Budlovsky T, Franck C, Eisenberg MJ. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials. Am J Cardiol. 2014 Mar 15;113(6):1075-82. - PubMed

Publication types

LinkOut - more resources